Assembly Biosciences, Inc. (ASMB)
| Market Cap | 440.67M -22.3% |
| Revenue (ttm) | 67.01M +80.2% |
| Net Income | -11.10M |
| EPS | -0.60 |
| Shares Out | 20.48M |
| PE Ratio | n/a |
| Forward PE | 413.85 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 272,711 |
| Open | 21.12 |
| Previous Close | 21.12 |
| Day's Range | 21.00 - 21.81 |
| 52-Week Range | 19.20 - 39.71 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 51.20 (+137.92%) |
| Earnings Date | Nov 12, 2026 |
About ASMB
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next g... [Read more]
Financial Performance
In 2025, Assembly Biosciences's revenue was $72.30 million, an increase of 153.52% compared to the previous year's $28.52 million. Losses were -$6.12 million, -84.76% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ASMB stock is "Strong Buy." The 12-month stock price target is $51.2, which is an increase of 137.92% from the latest price.
News
Assembly Biosciences Transcript: UBS Global Biopharma Conference 2026
HDV and Gilead-led HSV-2 phase II data are expected in H2 2027, with PBC/PSC data in H1 2028. ABI-6250’s oral NTCP mechanism spans HDV and cholestatic disease, while opt-in rights and 40/60 economics shape development options.
Assembly Biosciences reports Q3 EPS (93c), consensus (49c)
Reports Q3 revenue $2.96M, consensus $7.26M. “This quarter, we rapidly advanced our liver disease program by initiating the Phase 2 study of ABI-6250 in chronic hepatitis delta virus and preparing…
Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
– Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection –
Assembly Biosciences Earnings release: Q3 2026
Assembly Biosciences released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Assembly Biosciences Quarterly report: Q3 2026
Assembly Biosciences has published its Q3 2026 quarterly earnings report on November 12, 2026.
Assembly Biosciences Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
2027 is expected to bring substantial data, including HSV-2 and hepatitis D programs, with PBC/PSC data expected in H1 2028. Cash runway extends well into 2029, while oral ABI-6250 is advancing across liver indications.
Assembly Biosciences price target lowered to $48 from $52 at UBS
UBS analyst Ashwani Verma lowered the firm’s price target on Assembly Biosciences (ASMB) to $48 from $52 and keeps a Buy rating on the shares.
Assembly Biosciences to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver d...
Assembly Biosciences doses first two participants in ABI-6250 Phase 2 study
Assembly Biosciences (ASMB) announced dosing of the first two participants in a Phase 2 clinical study of ABI-6250, the company’s investigational oral small-molecule entry inhibitor candidate, in part...
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the four...
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction
Assembly Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Multiple antiviral programs are advancing, with key phase II studies for HDV and cholestatic liver diseases planned through 2027. Strategic collaboration with Gilead provides significant milestone and royalty potential, while a strong cash position supports ongoing development and pipeline expansion.
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver ...
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –
Assembly Biosciences Slides: Corporate presentation
Assembly Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 4, 2026.
Assembly Biosciences price target raised to $53 from $45 at Mizuho
Mizuho analyst Salim Syed raised the firm’s price target on Assembly Biosciences (ASMB) to $53 from $45 and keeps an Outperform rating on the shares. The firm updated the company’s…
Assembly Biosciences initiated with a Buy at UBS
UBS initiated coverage of Assembly Biosciences (ASMB) with a Buy rating and $52 price target The company has a “de-risked” antiviral platform, anchored by Gilead’s development of the herpes simplex…
Assembly Biosciences reports Q2 EPS (20c), consensus (52c)
Reports Q2 revenue $13.37M, consensus $6.45M. “During the second quarter, we advanced several important strategic priorities, including expanding ABI-6250 into cholestatic liver diseases and strengthe...
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) –
Assembly Biosciences Quarterly report: Q2 2026
Assembly Biosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Assembly Biosciences Earnings release: Q2 2026
Assembly Biosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Assembly Biosciences Slides: Corporate presentation
Assembly Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Assembly Biosciences price target raised to $45 from $40 at Mizuho
Mizuho raised the firm’s price target on Assembly Biosciences (ASMB) to $45 from $40 and keeps an Outperform rating on the shares. The firm updated the company’s model post the…
Assembly Biosciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing HSV-2 and liver disease programs, with strong phase I data and a key partnership accelerating HSV-2 development. Upcoming milestones include a profit-share decision, phase II data for HSV-2 and hep delta, and expansion into cholestatic liver diseases.
Assembly Biosciences Transcript: AGM 2026
The meeting covered board elections, executive compensation, auditor ratification, and amendments to incentive and stock purchase plans. All proposals passed with a quorum present, and no questions were raised by shareholders.